⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1954984 | 0.88 | — | — | |
| SCHEMBL19424916 | 0.78 | BCL2 (0.67) | — | |
| SCHEMBL1956034 | 0.78 | BCL2 (0.69) | — | |
| SCHEMBL1742960 | 0.77 | BCL2 (0.72) | — | |
| SCHEMBL1742180 | 0.77 | BCL2 (0.63) | — | |
| SCHEMBL1743247 | 0.76 | BCL2 (0.74) | — | |
| SCHEMBL1742388 | 0.76 | BCL2 (0.65) | — | |
| SCHEMBL1958412 | 0.76 | BCL2 (0.65) | — | |
| SCHEMBL1743317 | 0.75 | BCL2 (0.73) | — | |
| SCHEMBL1743602 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | claimed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | claimed |
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |